Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1832 (LINC01832) is an autonomously transcribed RNA gene that does not encode a protein and is classified within the long intergenic non-coding RNA (lincRNA) family[1][5]. LincRNAs generally regulate gene expression, modulate chromatin architecture, and participate in transcriptional and epigenetic regulation in a position- and tissue-specific manner[5]. Most lincRNAs, including LINC01832, remain poorly annotated, and their individual functions are inferred primarily from family-level analysis. They are not conventional therapeutic targets such as receptors, ion channels, enzymes, or transporters, and currently there are no drugs known to specifically act on LINC01832 nor clinical biomarker usage established for it[1][5]. If more detailed pathway or phenotype data are needed for LINC01832 specifically, further experimental evidence or published functional studies would be required.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1832 (LINC01832).